BioPharma
Queen Street Analytics' weekly digest of regulatory developments, legislative discussions, political announcements and other government-related news in biotech, pharmaceutical manufacturing, drug distribution and pricing, the life sciences and medical research.
QSA's Week in BioPharma (#3, 2025)
Canada-Ontario rare diseases agreement; Supreme Court decision on pharma accountability; AstraZeneca's $820M Ontario investment; Kinectrics' isotope production boost; AI in drug discovery growth.
QSA's Week in BioPharma (#2, 2025)
Canada signs $32M drug access deal; MPs debate Pharmacare delays; Updated CIHR grant data published.
QSA's Week in BioPharma (#1, 2025)
Canada, Saskatchewan boost rare disease drug access; MPs call for healthcare transformation; flu vaccination campaign kicks off.
QSA's Holiday Break in BioPharma (Issue #11, 2024)
Agile licensing changes; Pharmacare funding concerns; Biologics regulation updates; Drug standards modernized; Labeling requirements revised.
QSA's Week in BioPharma (#10, 2024)
SR&ED tax incentive program reforms announced; Canada Gazette updates drug and medical device fees; Patent Act fee adjustments scheduled.
QSA's Week in BioPharma (#9, 2024)
Aramis Biotechnologies secures $40M; Alberta drug access deal; PMPRB report release; R&D spending climbs; CEPA waivers for biopharma.